Patent to COVID-19 vaccine
国内首个新冠疫苗专利

China has granted its first COVID-19 vaccine patent to the adenovirus vector vaccine developed by Chen Wei of the Academy of Military Medical Sciences and Chinese biotech company CanSino Biologics, according to the National Intellectual Property Administration.
据国家知识产权局消息，由军事医学研究院陈薇及我国生物科技公司康希诺生物联合申报的腺病毒载体新冠疫苗专利申请近日获批，这是我国首个新冠疫苗专利。

The patent was submitted for application on March 18, and was approved on Aug 11, according to the patent document.
专利文件显示，该项专利于今年3月18日申请，8月11日获得授权。

The vaccine, dubbed "Ad5-nCoV", uses a weakened common cold virus to introduce genetic material from the novel coronavirus into the human body. The goal is to train the body to produce antibodies that recognize the coronavirus's spike protein and fight it off.
这款名为“Ad5-nCoV”的疫苗使用一种减毒普通感冒病毒为载体，将新冠病毒的遗传物质传递给人体细胞，目的是训练人体产生能识别并对抗新冠病毒突刺蛋白的抗体。

The phase-two clinical trial of the vaccine has found it is safe and can induce an immune response, according to research published in the journal Lancet last month.
该疫苗的二期临床试验结果于上月发表在《柳叶刀》期刊上，试验显示该疫苗安全，且可诱发免疫反应。

The phase-three clinical trial, which will include more participants and be conducted overseas, is currently in the pipeline.
三期临床试验将在海外更多受试者中进行，目前正在推进。